Infliximab in the Treatment of Recalcitrant Idiopathic Orbital Inflammation

In Brief A 15-year-old boy had bilateral idiopathic orbital inflammation refractory to treatment with corticosteroids. He was not only unresponsive to subsequent therapy with methotrexate but also had elevation of serum liver enzymes. In an attempt to minimize further side effects of corticosteroids and to avoid external beam radiation in an adolescent, we began treatment with infliximab, an anti–tumor necrosis-α antibody. His symptoms resolved and his disease has not recurred. Use of infliximab may be useful in the treatment of recalcitrant idiopathic orbital pseudotumor. Infliximab, an anti–tumor necrosis-α antibody, may be a novel agent for the treatment of recalcitrant idiopathic orbital pseudotumor.